PSNL News and Press, Personalis Inc. From 08/05/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cathie Wood’s exchange-traded funds (ETFs) received a breath of fresh air this week. The ARK Innovation ETF (NYSEMKT: ARKK ) ended the period up over 12%. Wood did admit that she believes the U.S. is current...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the 7 th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022. About Personalis Personalis, Inc...

Personalis, Inc. (PSNL) Q2 2022 Earnings Conference Call August 03, 2022 05:00 PM ET Company Participants Caroline Corner - Investor Relations John West - President & Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Part...

Personalis press release ( NASDAQ: PSNL ): Q2 GAAP EPS of -$0.60 (vs. -$0.34 Y/Y) beats by $0.03 . Revenue of $18.2M (-16.0% Y/Y) beats by $2.69M . FY22 revenue outlook is between $62.0M and $67.0M (vs. consensus of $64.54M). For further details see: ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022. Second Quarter and Recent Highlights Reported quarterly revenue of $18.2 million in the second quarter of 202...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis’ U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis ...

Personalis ( NASDAQ: PSNL ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.58 (-70.6% Y/Y) and the consensus Revenue Estimate is $15.51M (-28.4% Y/Y). Over the last 3 months, EPS estimates ha...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022. In conjunction with the release, Personalis will host a conference call and webcast that da...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, has added another patent family to its molecular residual disease (MRD)-related IP portfolio, with priority to January 2013. US Patent No. 11,384,394 describes the detection of MRD and recurrence by using who...